share_log

東陽光長江藥業：截至二零二四年六月三十日止六個月的中期業績公告

HEC CJ PHARM: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED 30 JUNE 2024

HKEX ·  Aug 30 20:30

Summary by Futu AI

宜昌東陽光長江藥業股份有限公司（「本公司」）公布截至2024年6月30日止六個月的中期業績。期內，公司營業額為人民幣2,454.8百萬元，較上年同期減少23.5%。毛利為人民幣1,949.2百萬元，下降24.0%。稅息、折舊及攤銷前溢利為人民幣1,064.2百萬元，減少33.1%。歸屬於公司權益持有人的溢利及全面收益總額為人民幣684.7百萬元，下降33.5%。每股基本及攤薄盈利均為人民幣0.78元。董事會決定不派發中期股息。公司在慢病線業務線取得顯著進展，胰島素產品營業額大幅增長140.7%，並有多款產品中標集中帶量採購。新藥線業務線磷酸依米他韋膠囊營業額增長188.5%，並成功進入國家醫保目錄。集採和新零售線業務線營業額增長60.8%，顯示公司業務管線逐漸進入收穫期。公司繼續加強內部管理，提升創新能力，致力於可持續發展。
宜昌東陽光長江藥業股份有限公司（「本公司」）公布截至2024年6月30日止六個月的中期業績。期內，公司營業額為人民幣2,454.8百萬元，較上年同期減少23.5%。毛利為人民幣1,949.2百萬元，下降24.0%。稅息、折舊及攤銷前溢利為人民幣1,064.2百萬元，減少33.1%。歸屬於公司權益持有人的溢利及全面收益總額為人民幣684.7百萬元，下降33.5%。每股基本及攤薄盈利均為人民幣0.78元。董事會決定不派發中期股息。公司在慢病線業務線取得顯著進展，胰島素產品營業額大幅增長140.7%，並有多款產品中標集中帶量採購。新藥線業務線磷酸依米他韋膠囊營業額增長188.5%，並成功進入國家醫保目錄。集採和新零售線業務線營業額增長60.8%，顯示公司業務管線逐漸進入收穫期。公司繼續加強內部管理，提升創新能力，致力於可持續發展。
Hec CJ Pharm Co., Ltd. (the "Company") announces its interim results for the six months ended June 30, 2024. During the period, the company's revenue was RMB 2,454.8 million, a decrease of 23.5% compared to the same period last year. Gross profit was RMB 1,949.2 million, a decrease of 24.0%. Profit before tax, interest, depreciation and amortization was RMB 1,064.2 million, a decrease of 33.1%. Total profit attributable to owners of the company and comprehensive income was RMB 684.7 million, a decrease of 33.5%. Basic and diluted earnings per share were RMB 0.78. The board of directors has decided not to declare an interim dividend. The company has achieved significant progress in the chronic disease business line, with a substantial increase of 140.7% in insulin product revenue and multiple products being...Show More
Hec CJ Pharm Co., Ltd. (the "Company") announces its interim results for the six months ended June 30, 2024. During the period, the company's revenue was RMB 2,454.8 million, a decrease of 23.5% compared to the same period last year. Gross profit was RMB 1,949.2 million, a decrease of 24.0%. Profit before tax, interest, depreciation and amortization was RMB 1,064.2 million, a decrease of 33.1%. Total profit attributable to owners of the company and comprehensive income was RMB 684.7 million, a decrease of 33.5%. Basic and diluted earnings per share were RMB 0.78. The board of directors has decided not to declare an interim dividend. The company has achieved significant progress in the chronic disease business line, with a substantial increase of 140.7% in insulin product revenue and multiple products being awarded centralized volume-based procurement. The revenue of the new drug business line, phosphatidylserine-metavir capsules, increased by 188.5% and successfully entered the national medical insurance catalog. The revenue of the joint procurement and new retail business line increased by 60.8%, demonstrating that the company's business pipeline is gradually entering the harvest period. The company continues to strengthen internal management, enhance innovation capabilities, and is committed to sustainable development.

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated